tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Maze Therapeutics price target raised to $34 from $19 at Guggenheim
PremiumThe FlyMaze Therapeutics price target raised to $34 from $19 at Guggenheim
1M ago
Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
Premium
The Fly
Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
2M ago
Maze Therapeutics Advances Clinical Programs Amid Financial Stability
Premium
Company Announcements
Maze Therapeutics Advances Clinical Programs Amid Financial Stability
2M ago
Maze Therapeutics announces results from Phase 1 trial of MZE782
PremiumThe FlyMaze Therapeutics announces results from Phase 1 trial of MZE782
2M ago
Maze Therapeutics prices 4M shares at $16.25 in private placement
Premium
The Fly
Maze Therapeutics prices 4M shares at $16.25 in private placement
2M ago
Maze Therapeutics Appoints Misbah Tahir as CFO
Premium
Company Announcements
Maze Therapeutics Appoints Misbah Tahir as CFO
2M ago
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
PremiumRatingsMaze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
3M ago
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
Premium
Ratings
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
3M ago
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
Premium
The Fly
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100